Holistic management of patients with progressive pulmonary fibrosis

Progressive pulmonary fibrosis (PF) is a complex interstitial lung disease that impacts substantially on patients' daily lives, requiring personalised and integrated care. We summarise the main needs of patients with PF and their caregivers, and suggest a supportive care approach. Individualised care, education, emotional and psychological support, specialised treatments, and better access to information and resources are necessary. Management should start at diagnosis, be tailored to the patient's needs, and consider end-of-life care. Pharmacological and non-pharmacological interventions should be individualised, including oxygen therapy and pulmonary rehabilitation, with digital healthcare utilised as appropriate. Further research is needed to address technical issues related to oxygen delivery and digital healthcare.To identify the main needs of patients with PF and their caregivers.To describe the components of a comprehensive approach to a supportive care programme for patients with PF.To identify further areas of research to address technical issues related to the management of patients with PF.

[1]  Miriam J. Johnson,et al.  European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease , 2023, European Respiratory Journal.

[2]  M. Kreuter,et al.  Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE , 2023, BMC Pulmonary Medicine.

[3]  G. Raghu,et al.  Idiopathic pulmonary fibrosis: state of the art for 2023 , 2023, European Respiratory Journal.

[4]  A. Białas,et al.  Study protocol for connective tissue disease-associated interstitial lung disease trial (TEL-CTD-ILD): A randomized controlled trial of a home-based telemonitoring of treatment effects , 2022, PloS one.

[5]  Miriam J. Johnson,et al.  Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial. , 2022, JAMA.

[6]  M. Kreuter,et al.  A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease , 2022, Respiratory Research.

[7]  M. Kreuter,et al.  Home monitoring in interstitial lung diseases. , 2022, The Lancet. Respiratory medicine.

[8]  G. Nakshbandi,et al.  Evaluation of home monitoring for patients with interstitial lung disease during the COVID-19 pandemic , 2022, 12.01 - Idiopathic interstitial pneumonias.

[9]  D. Brooks,et al.  Non-pharmacological Management of Non-productive Chronic Cough in Adults: A Systematic Review , 2022, Frontiers in Rehabilitation Sciences.

[10]  C. McDonald,et al.  Multidisciplinary Care and Prognosis in Patients With COPD and Interstitial Lung Disease Prescribed Long-Term Oxygen Therapy , 2022, Respiratory care.

[11]  O. Hilberg,et al.  Effect of a Telerehabilitation program in sarcoidosis , 2022, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  R. Llinas,et al.  The telemedicine experience: using principles of clinical excellence to identify disparities and optimize care , 2022, Medicine.

[13]  M. Mura,et al.  Nutrition implications of intrinsic restrictive lung disease. , 2022, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[14]  M. Strek,et al.  Cough-specific Quality of Life Predicts Disease Progression Among Patients with Interstitial Lung Disease: Data from the Pulmonary Fibrosis Foundation Patient Registry. , 2022, Chest.

[15]  V. Cottin,et al.  The Burden of Progressive-Fibrosing Interstitial Lung Diseases , 2022, Frontiers in Medicine.

[16]  B. Hope-Gill,et al.  Telephone Clinics During the Covid-19 Pandemic—The Experiences of Interstitial Lung Disease Patients and Their Carers , 2022, Journal of patient experience.

[17]  G. Tikellis,et al.  Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia , 2021, Respirology.

[18]  L. Boulet,et al.  Chronic cough: Investigations, management, current and future treatments , 2021, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.

[19]  A. Russell,et al.  Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study , 2021, BMJ supportive & palliative care.

[20]  K. Guntupalli,et al.  Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. , 2021, Respiratory medicine.

[21]  O. Hilberg,et al.  Tele-Rehabilitation Program in Idiopathic Pulmonary Fibrosis—A Single-Center Randomized Trial , 2021, International journal of environmental research and public health.

[22]  K. Lindell,et al.  A scoping review of unmet needs of caregivers of patients with pulmonary fibrosis , 2021, Current opinion in supportive and palliative care.

[23]  M. Kreuter,et al.  Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study , 2021, Thorax.

[24]  C. Moor,et al.  The use of online visual analogue scales in idiopathic pulmonary fibrosis , 2021, European Respiratory Journal.

[25]  P. Spagnolo,et al.  Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. , 2021, The Lancet. Respiratory medicine.

[26]  M. Kreuter,et al.  Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era , 2021, ERJ Open Research.

[27]  C. Vancheri,et al.  Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study , 2021, Advances in Therapy.

[28]  B. Calton,et al.  Better Together: A Mixed-Methods Study of Palliative Care Co-Management for Patients with Interstitial Lung Disease. , 2021, Journal of palliative medicine.

[29]  G. Raghu,et al.  R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life , 2021, European Respiratory Journal.

[30]  V. Cottin,et al.  Care Delivery Models and Interstitial Lung Disease: The Role of the Specialized Center. , 2021, Clinics in chest medicine.

[31]  S. Keshavjee,et al.  Telerehabilitation for Lung Transplant Candidates and Recipients During the COVID-19 Pandemic: Program Evaluation , 2021, JMIR mHealth and uHealth.

[32]  T. Geiser,et al.  Incidence and prognostic significance of hypoxemia in fibrotic interstitial lung disease: an international cohort study. , 2021, Chest.

[33]  J. Seabrook,et al.  Exercise capacity and its relationship with body composition and nutrition status in patients with interstitial lung disease. , 2021, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[34]  J. Seabrook,et al.  Fat-Free Mass Index Controlled for Age and Sex and Malnutrition Are Predictors of Survival in Interstitial Lung Disease , 2021, Respiration.

[35]  D. Bushnell,et al.  The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease , 2021, ERJ Open Research.

[36]  T. Corte,et al.  Nutritional status and quality of life in interstitial lung disease: a prospective cohort study , 2021, BMC Pulmonary Medicine.

[37]  I. Noth,et al.  Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial , 2021, European Respiratory Journal.

[38]  A. Holland,et al.  Pulmonary rehabilitation for interstitial lung disease: Referral and patient experiences , 2021, Chronic respiratory disease.

[39]  S. Knight,et al.  Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[40]  M. Kool,et al.  Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study , 2020, BMC Pulmonary Medicine.

[41]  A. Crispin,et al.  Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study , 2020, Respiratory Research.

[42]  Y. Lacasse,et al.  Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. , 2020, The New England journal of medicine.

[43]  E. Wouters,et al.  Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[44]  M. Humbert,et al.  Sleep-related breathing disorders and pulmonary hypertension , 2020, European Respiratory Journal.

[45]  O. Hilberg,et al.  Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease – a randomised placebo-controlled trial , 2020, Respiratory Research.

[46]  S. Stanojevic,et al.  Deep-learning algorithm helps to standardise ATS/ERS spirometric acceptability and usability criteria , 2020, European Respiratory Journal.

[47]  A. Yohannes.  Depression and anxiety in patients with interstitial lung disease , 2020, Expert review of respiratory medicine.

[48]  M. Artés,et al.  The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach , 2020, Advances in Therapy.

[49]  C. Moor,et al.  Managing Fatigue in Patients With Interstitial Lung Disease , 2020, Chest.

[50]  G. Tikellis,et al.  The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review , 2020, European Respiratory Review.

[51]  N. Chavannes,et al.  Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial. , 2020, American journal of respiratory and critical care medicine.

[52]  Mark G. Jones,et al.  Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? , 2020, ERJ Open Research.

[53]  I. Moore,et al.  Understanding cough in interstitial lung disease: a cross‐sectional study on the adequacy of treatment , 2020, Internal medicine journal.

[54]  H. Almond.  Patient support groups are a lifeline for those with idiopathic pulmonary fibrosis. , 2020, The Lancet Respiratory Medicine.

[55]  Sana Mohammed,et al.  Nonpharmacological cough control therapy for chronic refractory cough and cough associated with underlying lung disease , 2020, ERJ Open Research.

[56]  T. To,et al.  Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. , 2019, Chest.

[57]  A. Prasse,et al.  Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey , 2019, ERJ Open Research.

[58]  M. Wijsenbeek,et al.  Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease. , 2019, American journal of respiratory and critical care medicine.

[59]  C. Osadnik,et al.  Effect of Pulmonary Rehabilitation on Symptoms of Anxiety and Depression in COPD: A Systematic Review and Meta-Analysis. , 2019, Chest.

[60]  J. Soriano,et al.  Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry , 2019, Respiratory Research.

[61]  H. Date,et al.  Nutrition‐related factors associated with waiting list mortality in patients with interstitial lung disease: A retrospective cohort study , 2019, Clinical transplantation.

[62]  K. Brown,et al.  Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[63]  H. Adamali,et al.  Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs , 2018, BMJ Open Respiratory Research.

[64]  C. Vancheri,et al.  Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study , 2018, Advances in Therapy.

[65]  S. Birring,et al.  Treatment of Interstitial Lung Disease Associated Cough: CHEST Guideline and Expert Panel Report , 2018, Chest.

[66]  S. Birring,et al.  Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[67]  J. Alison,et al.  Telerehabilitation for chronic respiratory disease , 2018, Cochrane Database of Systematic Reviews.

[68]  C. Moor,et al.  A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers , 2018, Respiratory Research.

[69]  Miriam J. Johnson,et al.  Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review , 2018, BMC Pulmonary Medicine.

[70]  C. Ryerson,et al.  Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD , 2018, Respirology.

[71]  Anne Marie Russell,et al.  Contemporary challenges for specialist nursing in interstitial lung disease , 2018, Breathe.

[72]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: pathogenesis and management , 2018, Respiratory Research.

[73]  M. Kool,et al.  Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis , 2018, European Respiratory Journal.

[74]  Sarah Meadows,et al.  Understanding the informational needs of patients with IPF and their caregivers: ‘You get diagnosed, and you ask this question right away, what does this mean?’ , 2018, BMJ open quality.

[75]  David I Beatson,et al.  Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia , 2017, Respirology.

[76]  H. Magnussen,et al.  Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis , 2017, BMC Pulmonary Medicine.

[77]  Eric Vittinghoff,et al.  Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.

[78]  W. Cooper,et al.  Health‐related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry , 2017, Respirology.

[79]  C. Ryerson,et al.  Cough is less common and less severe in systemic sclerosis‐associated interstitial lung disease compared to other fibrotic interstitial lung diseases , 2017, Respirology.

[80]  A. Sheel,et al.  Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease , 2017, European Respiratory Journal.

[81]  A. Russell,et al.  Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. , 2016, American journal of respiratory and critical care medicine.

[82]  A. Nelson,et al.  The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study , 2015, BMC Pulmonary Medicine.

[83]  P. Frith,et al.  Clinical Practice Guideline on Adult Domiciliary Oxygen Therapy: Executive summary from the Thoracic Society of Australia and New Zealand , 2015, Respirology.

[84]  W. Wuyts,et al.  European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers , 2015, European Respiratory Journal.

[85]  W. MacNee,et al.  British Thoracic Society guidelines for home oxygen use in adults: accredited by NICE , 2015, Thorax.

[86]  T. Welte,et al.  Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry , 2015, European Respiratory Journal.

[87]  H. Collard,et al.  Pulmonary rehabilitation for interstitial lung disease. , 2010, Chest.

[88]  D. Jensen,et al.  Mechanisms of activity-related dyspnea in pulmonary diseases , 2009, Respiratory Physiology & Neurobiology.